文献速递肺外科

肺癌手术切除的初始与纵向成本

Initial and Longitudinal Cost of Surgical Resection for Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2020-10-05

本研究基于STS通用胸外科数据库与Medicare理赔数据链接,描述了2008至2013年间接受手术切除的65岁及以上NSCLC患者的初始及4年资源使用与成本。结果显示,切除住院平均6天、费用31,900美元;4年累计费用从I期的131,032美元到IV期的205,368美元不等。在I期肺叶切除患者中,微创手术的4年费用低于开胸手术(120,346美元对136,250美元)。

要点

  • NSCLC手术切除的4年累计费用随病理分期增加而升高。
  • I期肺叶切除患者中,微创手术的4年费用低于开胸手术。
  • 术后90天内费用随分期增加明显,之后各分期季度均值趋于相近。

核心结论

  • NSCLC手术切除的4年成本可观,且随病理分期增加而升高。
  • I期肺叶切除患者中,选择微创手术者成本较低,尤其在90天内。

研究设计与样本

  • 使用STS通用胸外科数据库的NSCLC切除临床数据链接Medicare理赔数据。
  • 纳入2008至2013年间接受手术治疗的65岁及以上NSCLC患者,费用以2017年美元计。
  • 采用逆概率加权处理行政删失,并按病理分期及I期肺叶切除的手术入路分层分析。

主要发现

  • 切除住院平均6天,费用31,900美元。
  • 术后90天内费用随分期增加:I期12,430美元,IV期26,350美元。
  • 4年累计费用从I期131,032美元到IV期205,368美元。
  • I期肺叶切除患者中,微创手术4年费用120,346美元,低于开胸手术的136,250美元。

临床怎么用

  • 评估肺癌手术价值时需考虑4年纵向成本,而不仅是初始住院费用。
  • 对I期肺叶切除患者,微创手术可能降低中长期费用。
  • 改善手术价值的潜在途径包括审慎使用术后重症监护及更早发现和治疗疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The longitudinal cost of treating patients with non-small cell lung cancer (NSCLC) undergoing surgical resection has not been evaluated. We describe initial and 4-year resource use and cost for NSCLC patients aged 65 years of age or greater who were treated surgically between 2008 and 2013. METHODS: Using clinical data for NSCLC resections from The Society of Thoracic Surgeons General Thoracic Surgery Database linked to Medicare claims, resource use and cost of preoperative staging, surgery, and subsequent care through 4 years were examined ($2017). Cost of hospital-based care was estimated using cost-to-charge ratios; professional services and care in other settings were valued using reimbursements. Inverse probability weighting was used to account for administrative censoring. Outcomes were stratified by pathologic stage and by surgical approach for stage I lobectomy patients. RESULTS: Resection hospitalizations averaged 6 days and cost $31,900. In the first 90 days, costs increased with stage ($12,430 for stage I to $26,350 for stage IV). Costs then declined toward quarterly means more similar among stages. Cumulative costs ranged from $131,032 (stage I) to $205,368 (stage IV). In the stage I lobectomy cohort, patients selected for minimally invasive procedures had lower 4-year costs than did thoracotomy patients ($120,346 versus $136,250). CONCLUSIONS: The 4-year cost of surgical resection for NSCLC was substantial and increased with pathologic stage. Among stage I lobectomy patients, those selected for minimally invasive surgery had lower costs, particularly through 90 days. Potential avenues for improving the value of surgical resection include judicious use of postoperative intensive care and earlier detection and treatment of disease.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Cowper PA, Feng L, Kosinski AS, et al. Initial and Longitudinal Cost of Surgical Resection for Lung Cancer. Ann Thorac Surg. 2020. PMID: 33031776. doi:10.1016/j.athoracsur.2020.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。